Dechra Pharmaceuticals PLC
DCHPF · OTC
6/30/2023 | 12/31/2022 | 6/30/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | 1.40 | -0.86 | 1.25 |
| FCF Yield | -0.00% | 1.36% | 0.74% | 1.42% |
| EV / EBITDA | -280.97 | 72.85 | 60.23 | 86.78 |
| Quality | ||||
| ROIC | -1.62% | 2.26% | 2.44% | 4.16% |
| Gross Margin | 54.96% | 57.90% | 56.12% | 56.77% |
| Cash Conversion Ratio | -0.24 | 2.28 | 1.99 | 2.16 |
| Growth | ||||
| Revenue 3-Year CAGR | 17.54% | 18.22% | 18.95% | 20.39% |
| Free Cash Flow Growth | -100.49% | 59.53% | -66.58% | 197.68% |
| Safety | ||||
| Net Debt / EBITDA | -27.05 | 8.97 | 3.41 | 2.98 |
| Interest Coverage | -2.22 | 5.27 | 8.53 | 13.67 |
| Efficiency | ||||
| Inventory Turnover | 0.80 | 0.71 | 0.87 | 0.96 |
| Cash Conversion Cycle | 124.26 | 77.88 | 76.14 | 31.00 |